Prophylactic deoxyspergualin treatment in living-related renal-transplant recipients transfused with donor-specific blood

Background. Deoxyspergualin (DSG) prophylaxis has improved long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood (DST). We examined the influence of acute rejection (AR) on graft survival in these patients. Methods. The study groups consisted of either historic control recipients without DSG (group A, n=64, 1985–1989) and recipients with DSG as the initial immunosuppressive agent (group B, n=76, 1989–1995). Both groups received DST from a one-haplotype identical donor and were treated with cyclosporine-based immunosuppression. Rejection was classified into accelerated rejection (Acc, within 5 days), AR (from 6 days–3 months), and late AR (LAR, from 4 months–1 year). Results. Overall 5-year graft survival rates were significantly higher in group B than group A (89.5 vs. 73.4%, P =0.0070). Each group was then subdivided on the basis of whether or not they had an episode of Acc, AR, or LAR. In group A, 5-year graft survival rate was not affected the presence or absence of Acc (75.0 vs. 73.1%), and it was influenced significantly by the presence or absence of AR (50.0 vs. 85.7%, P =0.0012) or LAR (46.7 vs. 81.6%, P <0.0001). In group B, 5-year graft survival did not change significantly by the presence or absence of Acc (100 vs. 88.7%), AR (81.8 vs. 92.6%), or LAR (81.0 vs. 92.7%). Conclusions. Prophylactic use of DSG in living-related renal-transplant recipients treated with DST improves long-term graft survival, even in patients with AR episodes.

[1]  F. Cosio,et al.  Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. , 2001, Kidney international.

[2]  A. Matas,et al.  Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. , 2000, Transplantation.

[3]  S. Hariharan,et al.  Improved graft survival after renal transplantation in the United States, 1988 to 1996. , 2000, The New England journal of medicine.

[4]  P. Nickerson,et al.  Does subclinical rejection contribute to chronic rejection in renal transplant patients? , 1999, Clinical transplantation.

[5]  J. Myles,et al.  Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome. , 1999, Transplantation.

[6]  A. Matas,et al.  Features of acute rejection that increase risk for chronic rejection. , 1999, Transplantation.

[7]  J. Alexander,et al.  Evaluation of pre- and posttransplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Cooperative Clinical Trials in Transplantation Research Group. , 1999, Transplantation.

[8]  E. Ritz,et al.  Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.

[9]  J. Ringers,et al.  Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure , 1999, The Lancet.

[10]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[11]  J. Fang,et al.  Diabetes mellitus after renal transplantation. , 1998, Transplantation proceedings.

[12]  N. Amada,et al.  Beneficial effects of 15-deoxyspergualin on late acute rejection occurring more than three months after renal transplantation. , 1998, Transplantation proceedings.

[13]  T. Kawai,et al.  Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. , 1998, Transplantation.

[14]  P. Vereerstraeten,et al.  Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. , 1997, Transplantation.

[15]  N. Amada,et al.  Donor-specific blood transfusion in living-related renal transplantation: fourteen-year experience. , 1997, Transplantation proceedings.

[16]  Kota Takahashi,et al.  Synergistic effect of donor-specific blood transfusion and a short course of deoxyspergualin in rat kidney transplantation , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[17]  T. Mohanakumar,et al.  Donor-specific transfusions have long-term beneficial effects for human renal allografts. , 1995, Transplantation.

[18]  J. Connett,et al.  Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. , 1994, JAMA.

[19]  H. Toma,et al.  Effect of deoxyspergualin on vascular rejection in canine kidney transplantation. , 1994, The Journal of urology.

[20]  N. Amada,et al.  Further study of deoxyspergualin prophylaxis in living related renal transplantation. , 1993, Transplantation proceedings.

[21]  K. Morikawa,et al.  THE SUPPRESSIVE EFFECT OF DEOXYSPERGUALIN ON THE DIFFERENTIATION OF HUMAN B LYMPHOCYTES MATURING INTO IMMUNOGLOBULIN‐PRODUCING CELLS , 1992, Transplantation.

[22]  L. Shaw,et al.  Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. , 1990, Transplantation proceedings.

[23]  T. Tokunaga,et al.  Mechanism of action of 15-deoxyspergualin. I. Suppressive effect on the induction of alloreactive secondary cytotoxic T lymphocytes in vivo and in vitro. , 1989, Immunology.

[24]  R. Stoney,et al.  Deliberate Donor‐specific Blood Transfusions Prior to Living Related Renal Transplantation: A New Approach , 1980, Annals of surgery.

[25]  J. Najarian,et al.  Development of diabetic vascular lesions in normal kidneys transplanted into patients with diabetes mellitus. , 1976, The New England journal of medicine.

[26]  O. Salvatierra,et al.  Are blood transfusions beneficial in the cyclosporine era? , 2004, Pediatric Nephrology.

[27]  D. Shoskes.  Immunologic tolerance in renal transplantation , 2004, World Journal of Urology.

[28]  W. Vaughn,et al.  Living-donor renal transplantation in SEOPF. The impact of histocompatibility, transfusions, and cyclosporine on outcome. , 1990, Transplantation.

[29]  D. Klassen,et al.  De novo diabetic nephropathy with functional impairment in a renal allograft. , 1986, American journal of nephrology.